GlassScriptPhysician profile
Jacob Nasser
NPI 1568084507
$2,592.52
in general payments reported to CMS, 2019-2025
13 companies · $1,510 in 2025
The $1,510 reported for 2025 was more than what 78% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $238 · 2023: $183 · 2024: $662 · 2025: $1,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,257 · Travel and Lodging: $1,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,256.56 |
| Travel and Lodging | $1,097.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $1,163.53 | 2024-2025 | |
| Smith+Nephew, INC. | $471.42 | 2023-2024 | Firstpass, Q-Fix, Osteoraptor |
| Acumed LLC | $238.14 | 2022 | |
| Abbvie INC. | $179.84 | 2023-2025 | |
| Mimedx Group, INC. | $178.16 | 2025 | |
| Stryker Corporation | $118.56 | 2024 | Omega |
| Organogenesis INC. | $113.40 | 2024-2025 | Via Matrix |
| Bioventus LLC | $26.55 | 2025 | Exogen Ultrasound Bone Healing System |
| Integra Lifesciences Corporation | $25.15 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Hydrofera LLC | $23.32 | 2023 | Hydrofera Blue |
| Bone Support INC. | $19.39 | 2025 | Ceramentbone Void Filler, Cerament G |
| Solventum Corporation | $18.30 | 2024 | V.A.C. Veraflo Cleanse Choice |
| Kerecis Limited | $16.76 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Nasser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.